Study of Chemo-Immunotherapy and Radiation for Esophageal Cancer with Blood Monitoring
Part of Cancer, Digestive system clinical trials.
This study tests a combination of chemotherapy, immunotherapy, and radiation for esophageal cancer that cannot be surgically removed. It also uses a simple blood test (ctDNA) to monitor your cancer's response throughout treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with squamous cell esophageal cancer that is stage II to IVa and cannot be treated with surgery (or you have chosen not to have surgery).
- You have not had prior radiation, chemotherapy, immunotherapy, or biologic therapy for esophageal cancer.
- You are in good enough health to have a performance status of 0 or 1 (able to carry on normal activities).
- Your blood counts and organ function (liver, kidneys, blood clotting) are within study limits.
- You must be willing to provide blood samples for ctDNA testing and agree to sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial tests whether adding immunotherapy to standard chemoradiation (chemotherapy plus radiation) can help preserve the esophagus and avoid surgery in people with resectable esophageal cancer. It aims to see if this combination is safer and more effective than current treatment.
This trial tests whether giving chemotherapy after surgery, based on a blood test that finds tiny bits of cancer DNA, can improve outcomes for people with esophageal squamous cell carcinoma. The blood test helps decide who might benefit from extra treatment.
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.